Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis
Ruxolitinib and lenalidomide may target distinct clinical and pathological manifestations of myelofibrosis and prevent therapy-related worsening of blood cell counts. To determine the efficacy and safety of the combination in patients with myelofibrosis, patients were given 15 mg ruxolitinib orally...
محفوظ في:
| المؤلفون الرئيسيون: | , , , , , , , , , , , , , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
Ferrata Storti Foundation
2015-08-01
|
| سلاسل: | Haematologica |
| الوصول للمادة أونلاين: | https://haematologica.org/article/view/7463 |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|